TNFSF10 and breast carcinoma: In addition, we pre-treated MDA-MB-231 breast cancer cells, which also harbor a hyper-methylated CDH1 promoter, with ML327 followed by TRAIL and demonstrated increased percentage of cells in the Sub G0 cell population as compared to vehicle pre-treated cells (Supplementary Figure 3D).